Ultimately, our goal is to develop a highly specific test that can detect HGSOC, the deadliest form of ovarian cancer, at its earlier stages, especially in women who are at increased risk of developing ovarian cancer (e.g., BRCA1 and BRCA2 mutation carriers). Here, BRCA2 is linked to ovarian cancer.